Replimune Group, Inc.

REPL

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$14.77

+US$0.72 · +5.12%

8月21日 16:00 ET

盘前

US$14.79

+US$0.02 · +0.14%

8月24日 8:50 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

36/ 100

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

动量

Neutral

情绪

Bearish

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Sushil Patel
上市以来: 2018年7月20日
雇员: 465

市场位置

日内区间

当前US$14.77，

US$13.81US$14.98

52周区间

当前US$14.77，

US$1.50US$15.705

开盘价: US$13.86
前收盘价: US$14.05
成交量: 296.95万; 0.46× 平均值
平均成交量: 643.53万; 日均成交量
市值: 12.41亿 USD
贝塔: 0.9; 市场参考 1
50天平均值: US$11.1625; 高于平均水平+32.32%
200天平均值: US$8.2605; 高于平均水平+78.80%

财务数据

财务快照

估值与收益率

企业价值: 6.13亿 USD
EV/EBITDA: -2.03×
盈利收益率: -44.22%
自由现金流收益率: -40.08%

盈利能力和效率

净资产收益率: -188.94%
资产收益率: -94.45%
投入资本回报率: -114.79%

财务健康

流动比率: 4.79×

财务报表

损益趋势

营业利润

−3.2亿 USD-22.28%

净利润

−3.14亿 USD-26.95%

项目（USD）	2026财年	2025财年	2024财年	2023财年	2022财年
销货成本	—	—	—	—	457.5万 USD
毛利	—	—	—	—	−457.5万 USD
研究与开发	2.21亿 USD	1.89亿 USD	1.75亿 USD	1.27亿 USD	8064.5万 USD
销售、一般及管理费用	9873.5万 USD	—	—	—	3626.4万 USD
营业费用	3.2亿 USD	2.62亿 USD	2.35亿 USD	1.77亿 USD	1.17亿 USD
利息收入	1362.5万 USD	2112万 USD	2335.6万 USD	1000.6万 USD	39万 USD
利息支出	885.9万 USD	789.3万 USD	666万 USD	416万 USD	222.3万 USD
折旧和摊销	333.2万 USD	592.9万 USD	508.3万 USD	244.7万 USD	457.5万 USD
营业利润	−3.2亿 USD	−2.62亿 USD	−2.35亿 USD	−1.77亿 USD	−1.21亿 USD
净利润	−3.14亿 USD	−2.47亿 USD	−2.16亿 USD	−1.74亿 USD	−1.18亿 USD

公司数据更新于 2026年8月24日。

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$18.67

上涨空间 26.40%

过去 12 个月12个月预测最高：US$20.00平均的：US$18.67最低：US$17.00

近期分析师行动

9 机构

REPL 消息

prnewswire.com2026年8月21日

Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action

SAN DIEGO, Aug. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group,…

阅读源码

globenewswire.com2026年8月21日

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options

阅读源码

globenewswire.com2026年8月21日

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune”…

阅读源码

globenewswire.com2026年8月21日

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to…

阅读源码

gurufocus.com2026年8月20日

REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm PR News

阅读源码

prnewswire.com2026年8月20日

REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were unresolved. NEW YORK,…

阅读源码